Madrigal Pharmaceuticals
Conshohocken, Pennsylvania, United States · Biopharma, Biotechnology, Healthcare
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH). The Company is focused on entering its next phase of expansion and growth as it ramps up for the launch of resmetirom and continues to build a more fully integrated organization.
Key facts
- Headquarters
- Conshohocken, Pennsylvania, United States
- Employees
- 637
- Industries
- Biopharma, Biotechnology, Healthcare
- Status
- Public (MDGL)
- Website
- https://www.madrigalpharma.com/
- Company page
Recent activity at Madrigal Pharmaceuticals
- : SEC 8-K (5.02): On August 11, 2026, Madrigal Pharmaceuticals, Inc. expanded its Board of Directors from eight to nine members, appointing Dr. John C. Reed, M.D., Ph.D. as a Class II director to fill the newly created vacancy. This appointment follows recommendations from the company's Nominating and Governance Committee and is effective as of August 11, 2026. Dr. Reed will receive an annual cash retainer of $50,000 and $10,000 for his service on the Science and Technology Committee, in addition to an equity grant valued at $675,000. This equity grant consists of stock options and restricted stock units, which will vest over the next two years contingent upon his continued service. No arrangements or understandings were disclosed regarding his appointment, and he has no material interest in any transactions requiring disclosure.
- : SEC 8-K (5.02): On June 17, 2026, Madrigal Pharmaceuticals, Inc. reported the approval of its 2026 Stock Plan and 2026 Employee Stock Purchase Plan during its annual stockholders meeting. This includes key details about the plans, which were previously adopted by the Board of Directors. Additionally, on June 16, 2026, the Board approved a Nonqualified Deferred Compensation Plan effective August 1, 2026, allowing certain executives and Board members to defer a significant portion of their compensation. This filing is significant as it reflects strategic financial planning and compensation structuring for the company's management, impacting future financial obligations and executive incentives.
- : SEC 8-K (5.02):
- : Madrigal Pharmaceuticals Enters First Amendment to Agreement with Roche
- : SEC 8-K (1.01): On January 29, 2026, Madrigal Pharmaceuticals, Inc. entered into the First Amendment to the Research, Development, and Commercialization Agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. This Amendment grants Madrigal full and exclusive rights to control patent term adjustments and extensions for Rezdiffra, impacting Roche's associated patents. Notably, the royalty payable to Roche on net sales will remain unchanged until certain patent term extensions expire. This strategic agreement reflects a significant shift in control over patent-related decisions that could enhance Madrigal's commercialization efforts for Rezdiffra.
- : SEC 8-K (1.01): On January 29, 2026, Madrigal Pharmaceuticals, Inc. entered into the First Amendment to the Research, Development, and Commercialization Agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. This amendment grants Madrigal full control over patent term adjustments and extensions for Rezdiffra, which includes patents owned by Roche and jointly owned by the parties. Consequently, the royalty payable to Roche based on net sales of Rezdiffra will remain unchanged until the expiration of the patent terms, significantly impacting the financial relationship between the two companies.
- : SEC 8-K (5.02):
- : Madrigal Pharmaceuticals Appoints David Soergel as Chief Medical Officer
- : Madrigal Pharmaceuticals Appoints Mardi C. Dier as Senior Vice President and Chief Financial Officer
- : Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer
Madrigal Pharmaceuticals funding history
| Date | Round | Amount |
|---|---|---|
| Dec 2022 | Funding Round | $300.0M |
| Apr 2016 | Seed | $3.4M |
Leadership
- David Soergel, Chief Medical Officer
- Mardi C. Dier, Vice President
- Mardi C. Dier, Chief Financial Officer
- Ronald Filippo, Chief Information Officer
- Carole Huntsman, Chief Commercial Officer
- Carole Huntsman, Chief Commercial Officer
- Bill Sibold, Chief Executive Officer
Verified email and direct lines for Madrigal Pharmaceuticals’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Madrigal Pharmaceuticals files 3 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Madrigal Pharmaceuticals in the news
- Madrigal Pharmaceuticals, Inc. (MDGL) Stock Price, News, Quote & History - Yahoo! Finance Canada (Oct 21, 2026)
- Madrigal pens $4.4B deal for Ribo's preclinical siRNA programs in latest Rezdiffra MASH play - Fierce Biotech (Feb 11, 2026)
- Madrigal Announces US Availability of Resmetirom (Rezdiffra), First Patients Treated for NASH - Patient Care Online (Apr 09, 2024)
- Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates - GlobeNewswire (May 06, 2026)
- Madrigal Expands its MASH Pipeline with Exclusive Global - GlobeNewswire (Jan 09, 2026)
- Madrigal Pharmaceuticals, Inc. (MDGL) stock price, news, quote and history - Yahoo Finance UK (Jan 29, 2017)
- Madrigal Pharmaceuticals (MDGL) Stock Price, News & Analysis - MarketBeat (Aug 11, 2016)
- Madrigal Presents Data Demonstrating Rezdiffra Reduced - GlobeNewswire (May 27, 2026)
Companies similar to Madrigal Pharmaceuticals
- Apellis Pharmaceuticals · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Crinetics Pharmaceuticals · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Aquestive Therapeutics, Inc. · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Os Therapies · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Lipella Pharmaceuticals · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
About Madrigal Pharmaceuticals: questions and answers
What does Madrigal Pharmaceuticals do?
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH). The Company is focused on entering its next phase of expansion and growth as it ramps up for the launch of resmetirom and continues to build a more fully integrated organization.
Where is Madrigal Pharmaceuticals headquartered?
Madrigal Pharmaceuticals is headquartered in Conshohocken, Pennsylvania, United States.
How many employees does Madrigal Pharmaceuticals have?
Madrigal Pharmaceuticals has about 637 employees.
Has Madrigal Pharmaceuticals raised funding?
Yes. Fundz has recorded 2 funding events for Madrigal Pharmaceuticals. The most recent, Funding Round of $300.0M, was in Dec 2022.
Who leads Madrigal Pharmaceuticals?
Mardi C. Dier is a Vice President at Madrigal Pharmaceuticals.
What is the latest news on Madrigal Pharmaceuticals?
On Aug 12, 2026, SEC 8-K (5.02): On August 11, 2026, Madrigal Pharmaceuticals, Inc. expanded its Board of Directors from eight to nine members, appointing Dr. John C. Reed, M.D., Ph.D. as a Class II director to fill the newly created vacancy. This appointment follows recommendations from the company's Nominating and
Is Madrigal Pharmaceuticals a public company?
Yes. Madrigal Pharmaceuticals is publicly traded under the ticker MDGL.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy